Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422265 · ClinicalTrials.gov registry record
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 56
- Enrollment target
NCT01422265: Completed study, sponsored by Genentech.
NCT01422265 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01422265 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred \> 6 months after first-line platinum-based chemotherapy (first recurrence). Patients who have completed second-line chemotherapy and are currently in observation or undergoing bevacizumab maintenance treatment will be eligible to participate in the study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-04 |
What the finished NCT01422265 record still lists
NCT01422265 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01422265 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01422265 about?
NCT01422265 is a clinical study titled "Patient Reported Symptoms in Ovarian Cancer (PRECISION)". This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred \> 6 months after first-line platinum-based...
What is the current status of trial NCT01422265?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2011-06. Estimated completion is 2015-04.
Who is sponsoring clinical trial NCT01422265?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia